CCM Biosciences, a Mount Laurel, NJ-based diversified biotechnology company, raised over $25M in Series A1 and A2 financings at a multi-hundred million dollar valuation.
Co-Founded by Dr. Raj Chakrabarti, Ph.D., Chairman and CEO, and Dr. Anisha Ghosh, Professor of Finance at McGill University, CCM Biosciences is a biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines. Novel therapeutic candidates and companion diagnostic tests are intended to treat various indications across precision oncology, rare diseases, autoimmune diseases, and age-related disorders.
CCM Biosciences possesses an expansive portfolio of novel product candidates including disruptive KRAS therapeutics that target the oncogene responsible for 25% of all cancers, selective first-in-class degraders of oncogenic kinases for lung cancer and leukemia, inhibitors of the master immune regulator cGAS for autoimmune disorders, therapies for nonsense mutations that account for 10% of all genetically inherited diseases, and disruptive drug candidates for mitochondrial upregulation relevant to a host of age-related disorders such as Parkinson’s, Alzheimer’s, and infertility
Several of its novel drug candidates have already reached significant development milestones. Investigational New Drug applications are expected to be filed with the FDA in the near future, based on clinical trial plans developed with medical experts from institutions including Cleveland Clinic and Ohio State University.
Its platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India.
The company is partnered with PMC Group for the Chemistry, Manufacturing, and Controls (CMC) of its drug programs. The CCM-PMC partnership offers a fully integrated ecosystem for the discovery, development, and manufacturing of drug candidates addressing some of the most significant unmet medical needs.
FinSMEs
30/08/2023